Molecular Targets for Cancer Therapy in the PI3K/AKT/mTOR Pathway

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F14%3A10146044" target="_blank" >RIV/00216208:11140/14:10146044 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00669806:_____/14:10146044

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.pharmthera.2013.12.004" target="_blank" >http://dx.doi.org/10.1016/j.pharmthera.2013.12.004</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.pharmthera.2013.12.004" target="_blank" >10.1016/j.pharmthera.2013.12.004</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Molecular Targets for Cancer Therapy in the PI3K/AKT/mTOR Pathway

Popis výsledku v původním jazyce

Aberrations in various cellular signaling pathways are instrumental in regulating cellular metabolism, tumor development, growth, proliferation, metastasis and cytoskeletal reorganization. The fundamental cellular signaling cascade involved in these processes, the phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of rapamycin (PI3K/AKT/mTOR), closely related to the mitogen-activated protein kinase (MAPK) pathway, is a crucial and intensively explored intracellular signaling pathway in tumorigenesis. Various activating mutations in oncogenes together with the inactivation of tumor suppressor genes are found in diverse malignancies across almost all members of the pathway. Substantial progress in uncovering PI3K/AKT/mTOR alterations and their roles in tumorigenesis has enabled the development of novel targeted molecules with potential for developing efficacious anticancer treatment. Two approved anticancer drugs, everolimus and temsirolimus, exemplify targeted inhibition of

Název v anglickém jazyce

Molecular Targets for Cancer Therapy in the PI3K/AKT/mTOR Pathway

Popis výsledku anglicky

Aberrations in various cellular signaling pathways are instrumental in regulating cellular metabolism, tumor development, growth, proliferation, metastasis and cytoskeletal reorganization. The fundamental cellular signaling cascade involved in these processes, the phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of rapamycin (PI3K/AKT/mTOR), closely related to the mitogen-activated protein kinase (MAPK) pathway, is a crucial and intensively explored intracellular signaling pathway in tumorigenesis. Various activating mutations in oncogenes together with the inactivation of tumor suppressor genes are found in diverse malignancies across almost all members of the pathway. Substantial progress in uncovering PI3K/AKT/mTOR alterations and their roles in tumorigenesis has enabled the development of novel targeted molecules with potential for developing efficacious anticancer treatment. Two approved anticancer drugs, everolimus and temsirolimus, exemplify targeted inhibition of

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

<a href="/cs/project/ED2.1.00%2F03.0076" target="_blank" >ED2.1.00/03.0076: Biomedicínské centrum Lékařské fakulty v Plzni</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pharmacology and Therapeutics

ISSN

0163-7258

e-ISSN

—

Svazek periodika

142

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

12

Strana od-do

164-175

Kód UT WoS článku

000334135000003

EID výsledku v databázi Scopus

—